Rabeprazole resubmitted for GORD in Japan
This article was originally published in Scrip
Executive Summary
Eisai has resubmitted an approval filing in Japan for its proton pump inhibitor Pariet (rabeprazole), for the additional indication of non-erosive gastro-oesophageal reflux disease (GORD/GERD).